Circio Holding
Circio Holding ASA (formerly Targovax ASA) is a Norwegian clinical-stage biotechnology enterprise specializing in the research, development, and commercialization of next-generation circular RNA (circRNA) gene therapies and cancer immunotherapies, prominently featuring its proprietary circRNA technology platform (circDirect) and targeted tumor-infiltrating therapies. The company conducts advanced preclinical and clinical research evaluating novel genetic constructs designed to improve stability and expression of therapeutic proteins for oncology and genetic diseases. Its core business operations encompass biotechnology R&D, circular RNA platform engineering, clinical trial execution, and collaborative biopharmaceutical licensing. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its research activities through public equity offerings, grants, and strategic research partnerships. Circio Holding holds a pioneering market position in circular RNA gene therapy development. The company is headquartered in Oslo, Norway, and its shares trade on Euronext Oslo Børs.
4 of the funds FundTelligence covers report a position in Circio Holding.
- Legal name
- Circio Holding ASA
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 4
Funds holding Circio Holding
- Danske Invest Norway Index Restricted — Danske Invest · 0.15 % (full portfolio disclosed, September 2026)
- DNB Norge Indeks — DNB · 0.12 % (full portfolio disclosed, September 2026)
- Storebrand Indeks Norge — Storebrand · 0.11 % (full portfolio disclosed, October 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.07 % (full portfolio disclosed, October 2026)